Multiple Myeloma Diagnosis
16 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What are the three diagnostic criteria for multiple myeloma?

Monoclonal protein (M-protein) in blood or urine, Bone marrow plasma cells ≥ 10%, and Evidence of end-organ damage (e.g., anemia, bone lesions, hypercalcemia, kidney disease).

What is the main difference between the International Staging System (ISS) and the Revised ISS (R-ISS)?

The R-ISS incorporates lactate dehydrogenase (LDH) levels and high-risk chromosomal abnormalities, in addition to β2-microglobulin and albumin levels.

What is the role of maintenance therapy in multiple myeloma treatment?

To prolong remission.

What is the mechanism of action of daratumumab in multiple myeloma treatment?

<p>It is an anti-CD38 monoclonal antibody.</p> Signup and view all the answers

What are the three main aspects of symptom management in multiple myeloma?

<p>Pain management, anemia management, and bone disease management.</p> Signup and view all the answers

How is relapsed disease defined in multiple myeloma?

<p>Disease progression after initial response.</p> Signup and view all the answers

What is the primary goal of autologous stem cell transplant (ASCT) in multiple myeloma treatment?

<p>To improve response rates and prolong progression-free survival.</p> Signup and view all the answers

What is the primary risk associated with allogenic stem cell transplant in multiple myeloma treatment?

<p>Graft-versus-host disease (GVHD).</p> Signup and view all the answers

What is the primary characteristic of multiple myeloma, and what is another name for this disease?

<p>Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. Another name for this disease is Kahler's disease or myelomatosis.</p> Signup and view all the answers

What are the three main risk factors for developing multiple myeloma?

<p>The three main risk factors for developing multiple myeloma are age (especially after 65), family history, and radiation exposure.</p> Signup and view all the answers

What are the common symptoms of multiple myeloma?

<p>Common symptoms of multiple myeloma include bone pain, fatigue, weakness, recurring infections, anemia, hypercalcemia, and kidney problems.</p> Signup and view all the answers

What are the diagnostic tests used to diagnose multiple myeloma?

<p>Diagnostic tests used to diagnose multiple myeloma include blood tests, urine tests, bone marrow biopsy, and imaging tests such as X-rays, CT scans, MRI scans, and PET scans.</p> Signup and view all the answers

How is multiple myeloma staged, and what is the significance of staging?

<p>Multiple myeloma is staged based on the severity of the disease, with Stage I being low tumor burden and minimal bone damage, Stage II being moderate tumor burden and moderate bone damage, and Stage III being high tumor burden and extensive bone damage.</p> Signup and view all the answers

What are the common complications of multiple myeloma?

<p>Common complications of multiple myeloma include bone damage, kidney damage, infections, anemia, and hypercalcemia.</p> Signup and view all the answers

What are the treatment options for multiple myeloma?

<p>Treatment options for multiple myeloma include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care.</p> Signup and view all the answers

What is the prognosis for multiple myeloma, and how does it vary by stage?

<p>The prognosis for multiple myeloma varies by stage, with a 5-year survival rate of 62% for Stage I, 45% for Stage II, and 29% for Stage III.</p> Signup and view all the answers

Study Notes

Diagnosis

  • Diagnostic criteria:
    • Monoclonal protein (M-protein) in blood or urine
    • Bone marrow plasma cells ≥ 10%
    • Evidence of end-organ damage (e.g., anemia, bone lesions, hypercalcemia, kidney disease)
  • Diagnostic tests:
    • Blood tests: complete blood count (CBC), serum protein electrophoresis (SPEP), serum free light chain (SFLC) assay
    • Urine tests: urine protein electrophoresis (UPEP), urine SFLC assay
    • Bone marrow biopsy and aspirate
    • Imaging studies: skeletal survey, PET/CT, MRI
  • Staging systems:
    • International Staging System (ISS): based on β2-microglobulin and albumin levels
    • Revised ISS (R-ISS): incorporates lactate dehydrogenase (LDH) levels and high-risk chromosomal abnormalities

Treatment Options

  • Induction therapy:
    • Combination of chemotherapy, immunomodulatory agents, and proteasome inhibitors
    • Examples: VRd (bortezomib, lenalidomide, dexamethasone), KRd (carfilzomib, lenalidomide, dexamethasone)
  • Maintenance therapy:
    • Lenalidomide or bortezomib to prolong remission
  • Targeted therapies:
    • Daratumumab (anti-CD38 monoclonal antibody)
    • Elotuzumab (anti-SLAMF7 monoclonal antibody)
    • Carfilzomib (proteasome inhibitor)
  • Supportive care:
    • Bisphosphonates for bone disease
    • Erythropoietin for anemia

Symptom Management

  • Pain management:
    • Opioids, NSAIDs, and bisphosphonates
    • Radiation therapy for bone pain
  • Anemia management:
    • Erythropoietin, iron supplements, and transfusions
  • Bone disease management:
    • Bisphosphonates, denosumab, and kyphoplasty
  • Infection management:
    • Antibiotics and antiviral medications
    • Vaccination against pneumococcal and influenza infections

Relapsed/Refractory Disease

  • Definition:
    • Relapsed: disease progression after initial response
    • Refractory: disease progression during or within 60 days of treatment
  • Treatment options:
    • Re-treatment with previous regimens
    • Alternative regimens (e.g., pomalidomide, ixazomib)
    • Clinical trials

Stem Cell Transplant

  • Autologous stem cell transplant (ASCT):
    • High-dose chemotherapy followed by infusion of patient's own stem cells
    • Improves response rates and prolongs progression-free survival
  • Allogenic stem cell transplant:
    • High-dose chemotherapy followed by infusion of donor stem cells
    • May offer curative potential, but associated with higher risk of graft-versus-host disease (GVHD)

Diagnosis

  • Monoclonal protein (M-protein) is present in blood or urine
  • At least 10% of bone marrow cells are plasma cells
  • Evidence of end-organ damage, such as anemia, bone lesions, hypercalcemia, or kidney disease, is present

Diagnostic Tests

  • Complete blood count (CBC) and serum protein electrophoresis (SPEP) are performed on blood samples
  • Urine protein electrophoresis (UPEP) and urine serum free light chain (SFLC) assay are performed on urine samples
  • Bone marrow biopsy and aspirate are performed to examine bone marrow cells
  • Imaging studies, such as skeletal survey, PET/CT, and MRI, are used to visualize the body

Staging Systems

  • International Staging System (ISS) is based on β2-microglobulin and albumin levels
  • Revised ISS (R-ISS) incorporates lactate dehydrogenase (LDH) levels and high-risk chromosomal abnormalities

Treatment Options

  • Induction therapy combines chemotherapy, immunomodulatory agents, and proteasome inhibitors
  • Examples of induction therapy regimens include VRd and KRd
  • Maintenance therapy uses lenalidomide or bortezomib to prolong remission
  • Targeted therapies include daratumumab, elotuzumab, and carfilzomib
  • Supportive care involves bisphosphonates, erythropoietin, and transfusions

Symptom Management

  • Pain management involves opioids, NSAIDs, bisphosphonates, and radiation therapy
  • Anemia management involves erythropoietin, iron supplements, and transfusions
  • Bone disease management involves bisphosphonates, denosumab, and kyphoplasty
  • Infection management involves antibiotics, antiviral medications, and vaccination against pneumococcal and influenza infections

Relapsed/Refractory Disease

  • Relapsed disease is defined as disease progression after initial response
  • Refractory disease is defined as disease progression during or within 60 days of treatment
  • Treatment options for relapsed/refractory disease include re-treatment with previous regimens, alternative regimens, and clinical trials

Stem Cell Transplant

  • Autologous stem cell transplant (ASCT) involves high-dose chemotherapy followed by infusion of patient's own stem cells
  • Allogenic stem cell transplant involves high-dose chemotherapy followed by infusion of donor stem cells

Definition and Overview

  • Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow, characterized by abnormal proliferation of plasma cells.
  • It is also known as Kahler's disease or myelomatosis.

Causes and Risk Factors

  • Age is a significant risk factor, especially after 65.
  • Having a family member with multiple myeloma increases the risk of developing the disease.
  • Exposure to high levels of radiation and certain chemicals, such as benzene, is a risk factor.
  • African Americans are more likely to develop multiple myeloma.

Symptoms

  • Bone pain, especially in the back, hips, or ribs, is a common symptom.
  • Fatigue, weakness, and recurring infections are also common symptoms.
  • Anemia, characterized by low red blood cell count, is often present.
  • Hypercalcemia, or high calcium levels, is another common symptom.
  • Kidney problems are also a common symptom.

Diagnosis

  • Complete blood count (CBC), blood chemistry tests, and serum protein electrophoresis (SPEP) are used in blood tests to diagnose multiple myeloma.
  • Urine protein electrophoresis (UPEP) is used in urine tests to diagnose multiple myeloma.
  • Bone marrow biopsy is used to examine bone marrow cells.
  • Imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, are used to diagnose multiple myeloma.

Staging and Prognosis

  • Multiple myeloma is staged based on the severity of the disease, with Stage I being the least severe and Stage III being the most severe.
  • Stage I has a 5-year survival rate of 62%, Stage II has a 5-year survival rate of 45%, and Stage III has a 5-year survival rate of 29%.

Treatment

  • Chemotherapy, targeted therapy, and immunotherapy are used to kill cancer cells and manage symptoms.
  • Stem cell transplantation is used to replace bone marrow with healthy stem cells.
  • Supportive care is used to manage symptoms and side effects.

Complications

  • Bone damage, including osteoporosis, fractures, and bone deformities, is a common complication.
  • Kidney damage, including kidney failure and chronic kidney disease, is a common complication.
  • Infections, including recurrent infections and sepsis, are a common complication.
  • Anemia, characterized by low red blood cell count, is a common complication.
  • Hypercalcemia, or high calcium levels, is a common complication.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Quiz Team

Description

Diagnosing multiple myeloma involves identifying monoclonal protein in blood or urine, bone marrow plasma cells, and evidence of end-organ damage. Various tests are used to confirm the diagnosis.

More Like This

Multiple Myeloma Quiz
10 questions

Multiple Myeloma Quiz

AchievableWilliamsite1275 avatar
AchievableWilliamsite1275
Multiple Myeloma Pathogenesis
5 questions

Multiple Myeloma Pathogenesis

ComfortableConnemara8040 avatar
ComfortableConnemara8040
Use Quizgecko on...
Browser
Browser